ID   FU-UR-1
AC   CVCL_6997
DR   Cosmic; 1184243
DR   Wikidata; Q54835253
RX   PubMed=15138551;
RX   PubMed=23288701;
CC   Population: Japanese.
CC   Doubling time: 32 hours (Note=At 51th passage) (PubMed=15138551).
CC   Sequence variation: Gene fusion; HGNC; HGNC:13825; ASPSCR1 + HGNC; HGNC:11752; TFE3; Name(s)=ASPSCR1-TFE3, ASPL-TFE3 (PubMed=15138551; PubMed=23288701).
CC   Derived from site: In situ; Retroperitoneal space; UBERON=UBERON_0003693.
DI   NCIt; C27891; Renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions
DI   ORDO; Orphanet_319308; MiT family translocation renal cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   24Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 16
//
RX   PubMed=15138551; DOI=10.3892/or.11.6.1169;
RA   Ishiguro M., Iwasaki H., Ohjimi Y., Kaneko Y.;
RT   "Establishment and characterization of a renal cell carcinoma cell
RT   line (FU-UR-1) with the reciprocal ASPL-TFE3 fusion transcript.";
RL   Oncol. Rep. 11:1169-1175(2004).
//
RX   PubMed=23288701; DOI=10.1002/path.4158; PMCID=PMC4083568;
RA   Kobos R., Nagai M., Tsuda M., Merl M.Y., Saito T., Lae M., Mo Q.-X.,
RA   Olshen A.B., Lianoglou S., Leslie C., Ostrovnaya I., Antczak C.,
RA   Djaballah H., Ladanyi M.;
RT   "Combining integrated genomics and functional genomics to dissect the
RT   biology of a cancer-associated, aberrant transcription factor, the
RT   ASPSCR1-TFE3 fusion oncoprotein.";
RL   J. Pathol. 229:743-754(2013).
//